606 related articles for article (PubMed ID: 18037317)
21. Fabry disease.
Tarabuso AL
Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
[TBL] [Abstract][Full Text] [Related]
22. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
[TBL] [Abstract][Full Text] [Related]
23. Clinical spectrum of Anderson Fabry disease in a Romanian family.
Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
[TBL] [Abstract][Full Text] [Related]
24. A case of multiple angiomas without any angiokeratomas in a female heterozygote with Fabry disease.
Mirceva V; Hein R; Ring J; Möhrenschlager M
Australas J Dermatol; 2010 Feb; 51(1):36-8. PubMed ID: 20148840
[TBL] [Abstract][Full Text] [Related]
25. [Psychiatric and neuropsychological signs and symptoms in patients with fabry disease: literature review].
Müller MJ; Müller KM; Dascalescu A; Whybra C; Baron K; Scheurich A; Mann K; Beck M; Schmidt LG; Fellgiebel A
Fortschr Neurol Psychiatr; 2005 Nov; 73(11):687-93. PubMed ID: 16283613
[TBL] [Abstract][Full Text] [Related]
26. Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: Natural history in males.
Oliveira JP; Nowak A; Barbey F; Torres M; Nunes JP; Teixeira-E-Costa F; Carvalho F; Sampaio S; Tavares I; Pereira O; Soares AL; Carmona C; Cardoso MT; Jurca-Simina IE; Spada M; Ferreira S; Germain DP
Eur J Med Genet; 2020 Feb; 63(2):103703. PubMed ID: 31200018
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.
Hopkin RJ; Cabrera GH; Jefferies JL; Yang M; Ponce E; Brand E; Feldt-Rasmussen U; Germain DP; Guffon N; Jovanovic A; Kantola I; Karaa A; Martins AM; Tøndel C; Wilcox WR; Yoo HW; Burlina AP; Mauer M
Mol Genet Metab; 2023 Feb; 138(2):106967. PubMed ID: 36709533
[TBL] [Abstract][Full Text] [Related]
28. Japanese patients with Fabry disease predominantly showing cardiac and neurological manifestation with novel missense mutation: R220P.
Fukutomi M; Tanaka N; Uchinoumi H; Kanemoto M; Nakao F; Yamada J; Kamei T; Takenaka T; Fujii T
J Cardiol; 2013 Jul; 62(1):63-9. PubMed ID: 23608164
[TBL] [Abstract][Full Text] [Related]
29. Screening for health-related quality of life and its determinants in Fabry disease: A cross-sectional multicenter study.
Winter Y; Hilz M; Beuschlein F; Tsukimura T; Seifritz E; Lenders M; Brand E; Hennermann JB; Nowak A
Mol Genet Metab; 2023 Nov; 140(3):107692. PubMed ID: 37703724
[TBL] [Abstract][Full Text] [Related]
30. Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.
Politei JM; Cabrera G; Amartino H; Valdez R; Masllorens F; Ripeau D; Antongiovanni N; Soliani A; Luna P; Cedrolla M; Fernandez S; Fainboim A
Int J Clin Pract; 2013 Jan; 67(1):66-72. PubMed ID: 23241050
[TBL] [Abstract][Full Text] [Related]
31. Fabry disease. A case report.
Kotnik J; Kotnik F; Desnick RJ
Acta Dermatovenerol Alp Pannonica Adriat; 2005 Mar; 14(1):15-9. PubMed ID: 15818441
[TBL] [Abstract][Full Text] [Related]
32. Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease.
Pereira EM; do Monte SJ; do Nascimento FF; de Castro JA; Sousa JL; Filho HC; da Silva RN; Labilloy A; Monte Neto JT; da Silva AS
Gene; 2014 Feb; 536(1):118-22. PubMed ID: 24334114
[TBL] [Abstract][Full Text] [Related]
33. Pediatric Fabry disease.
Ries M; Gupta S; Moore DF; Sachdev V; Quirk JM; Murray GJ; Rosing DR; Robinson C; Schaefer E; Gal A; Dambrosia JM; Garman SC; Brady RO; Schiffmann R
Pediatrics; 2005 Mar; 115(3):e344-55. PubMed ID: 15713906
[TBL] [Abstract][Full Text] [Related]
34. Disease manifestations and X inactivation in heterozygous females with Fabry disease.
Maier EM; Osterrieder S; Whybra C; Ries M; Gal A; Beck M; Roscher AA; Muntau AC
Acta Paediatr Suppl; 2006 Apr; 95(451):30-8. PubMed ID: 16720462
[TBL] [Abstract][Full Text] [Related]
35. Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community.
Wanner C; Ortiz A; Wilcox WR; Hopkin RJ; Johnson J; Ponce E; Ebels JT; Batista JL; Maski M; Politei JM; Martins AM; Banikazemi M; Linhart A; Mauer M; Oliveira JP; Weidemann F; Germain DP
Mol Genet Metab; 2023 Jul; 139(3):107603. PubMed ID: 37236007
[TBL] [Abstract][Full Text] [Related]
36. Major Organic Involvement in Women with Fabry Disease in Argentina.
Perretta F; Antongiovanni N; Jaurretche S
ScientificWorldJournal; 2018; 2018():6515613. PubMed ID: 29950951
[TBL] [Abstract][Full Text] [Related]
37. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients.
Navarro C; Teijeira S; Dominguez C; Fernandez JM; Rivas E; Fachal C; Barrera S; Rodriguez C; Iranzo P
Acta Neuropathol; 2006 Feb; 111(2):178-85. PubMed ID: 16463201
[TBL] [Abstract][Full Text] [Related]
38. Fabry disease: molecular genetics of the inherited nephropathy.
Desnick RJ; Astrin KH; Bishop DF
Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
[TBL] [Abstract][Full Text] [Related]
39. Pedigree analysis of Mexican families with Fabry disease as a powerful tool for identification of heterozygous females.
Gutiérrez-Amavizca BE; Orozco-Castellanos R; R Padilla-Gutiérrez J; Valle Y; Figuera LE
Genet Mol Res; 2014 Aug; 13(3):6752-8. PubMed ID: 25177955
[TBL] [Abstract][Full Text] [Related]
40. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
Desnick RJ; Banikazemi M
Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
